查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1868243

固態器官移植排斥反應市場（依排斥類型、捐贈方式、移植器官類型和最終用戶分類）－2025-2032年全球預測

Solid Organ Transplantation Rejection Market by Rejection Type, Offering, Type Of Organ Transplant, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，固態器官移植排斥治療市場將成長至 134.1 億美元，複合年成長率為 5.50%。

關鍵市場統計數據
基準年 2024 87.4億美元
預計年份：2025年 91.9億美元
預測年份 2032 134.1億美元
複合年成長率 (%) 5.50%

了解固態器官移植排斥反應在臨床、診斷和治療方面不斷演變的現狀，以及整合式照護路徑和創新方面的策略必要性。

固態器官移植仍然是現代醫學中最具變革性的治療方法之一，但排斥反應仍然是臨床和運作中面臨的核心挑戰。隨著手術效果的改善，人們的關注點已轉向驅動急性、慢性及超急性排斥反應的各種免疫反應，每種反應都需要不同的診斷、監測和治療方法。免疫學、診斷學和治療學之間不斷演變的相互作用，正迫使臨床醫生、醫院系統、製造商和支付方重新評估治療路徑及其相關基礎設施。

診斷、治療、數位整合、監管重點和跨部門合作方面的變革性變化正在重塑移植排斥反應的檢測和管理方式。

移植排斥反應的管理格局正經歷多重並行變革，這些變革共同重塑治療標準。其中一個關鍵變化是精準診斷技術的成熟。血液檢測、先進的影像學檢查和精密的組織切片檢查技術正在融合，從而能夠早期、特異性檢測免疫介導的損傷。診斷技術的進步與免疫調節劑的改進相輔相成，包括改良的抗體療法、標靶抗代謝藥物、最佳化的Calcineurin酶抑制劑方案以及類固醇減量策略，這些都為更個人化的免疫抑制治療創造了可能，從而降低排斥反應和長期毒性。

評估自 2025 年起生效的美國關稅變化對移植醫學的器官取得、製造地、國際合作和供應鏈韌性的影響。

預計2025年生效的美國關稅將進一步加劇現有供應鏈的壓力，並促使許多移植相關人員重新評估籌資策略。血液檢測、診斷成像平台和組織切片檢查處理中使用的設備和試劑通常依賴跨國供應鏈，而不斷上漲的進口成本和複雜的海關程序正在影響採購決策、庫存管理實踐和供應商多元化。因此，一些移植中心和專科診所正在加快關鍵庫存在地化的步伐，協商簽訂多年供應商協議，並採用包含許多國內可用組件的替代技術。

整合排斥表現型、診斷方法、治療方法分類、器官特異性因素以及醫療環境影響等細分領域的指南，以指導策略優先排序。

要深入了解市場動態，需要檢驗構成移植排斥反應管理的關鍵細分領域。就排斥反應類型而言，急性排斥反應需要快速診斷確認和有效的免疫抑制治療；慢性排斥反應需要長期監測和採取措施來減輕移植物的進行性劣化；而超急性排斥反應則需要即時進行手術全期識別和干涉。因此，每種排斥反應表現型都有其獨特的臨床重點和技術要求。

美洲、歐洲、中東和非洲以及亞太地區的區域模式和採用趨勢將影響研究重點、臨床整合以及移植創新成果的取得。

區域差異深刻影響移植排斥預防和管理創新技術的採納和融入醫療保健系統的方式。在美洲，高容量的移植中心和完善的報銷機制促進了先進診斷技術和新型治療方法的快速應用，而區域間醫療資源分配的差異則需要重點關注如何擴大醫療服務能力並確保公平分配。在歐洲、中東和非洲，不同的法規結構和醫療體系模式導致了技術應用的不平衡。學術機構和國家級轉診醫院主導臨床研究和最佳實踐的推廣，而其他地區則專注於務實、資源高效的方案。

透過競爭與合作並存的公司洞察，揭示診斷創新者、治療藥物開發商和供應鏈策略家如何為臨床和營運領導地位做好準備。

移植排斥反應管理領域的競爭格局呈現出成熟醫療公司與專業創新企業並存的局面，二者都在推動技術進步與臨床應用。診斷公司正投資開發可擴展的平台，用於靈敏的血液檢測和組織分析；影像供應商則專注於增強移植監測和功能評估的影像技術。製藥和生物技術公司不斷改進免疫抑制療法，推進針對特定免疫路徑的抗體和小分子藥物研發項目，並經常與學術機構合作，以檢驗臨床終點和安全性。

為高階主管和臨床領導者提供切實可行的建議，以加速診斷技術的普及應用、加強供應鏈、協調夥伴關係，並在醫療機構中擴大公平的醫療服務取得途徑。

產業領導者應推動一系列合作，將科學進步轉化為更長的移植器官壽命和可衡量的患者療效改善。首先，優先投資於能夠實現早期、非侵入性檢測的診斷技術，將提高臨床應對力，並減少對侵入性手術的依賴。其次，將「診斷-治療演算法」納入臨床工作流程，並輔以可互通的醫療資訊科技、決策支援和臨床醫師培訓，將加速這些演算法的推廣應用，並提高各醫院、移植中心和專科診所之間診療服務的一致性。此外，各機構應促進策略聯盟，將診斷設備製造商、藥物研發商和研究機構聯合起來，共同設計檢驗研究和真實世界證據項目，以證明這些技術在心臟、腎臟、肝臟、肺臟和胰臟移植中的臨床效用。

採用透明的混合方法調查方法，結契約儕審查的證據、專家訪談和操作證據，得出可靠的實用結論。

本報告的分析採用了一種嚴謹的混合調查方法，旨在確保其可靠性、相關性和實用性。二級研究系統性地回顧了同儕審查的臨床文獻、監管申報文件和已發表的技術文件，以描述各種排斥表現型的診斷技術、治療機制和臨床管理策略。此外，還開展了一級研究，對移植臨床醫生、實驗室主任、器官獲取負責人和行業高管進行了結構化訪談，以了解他們對未滿足的需求、實施障礙和實際應用促進因素的觀點。

結論整合了臨床和策略要務，旨在透過診斷、治療、協作和強力的實施策略來提高移植器官的長期存活率。

固態器官移植正處於一個十字路口，科學創新、臨床實務和系統層面的考量在此交匯，共同影響著病患的預後。診斷和治療方法的進步具有降低急性、慢性及超急性排斥反應發生率和影響的真正潛力。然而，要實現這一潛力，需要製造商、臨床醫生、醫療系統和政策制定者之間的協調行動。對非侵入性監測、實證醫學、互通工作流程和穩健的供應鏈進行策略性投資，是把科學進步轉化為常規臨床效益的關鍵。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 開發供體特異性生物標記用於早期檢測移植排斥反應
  • 基於患者臨床數據的機器學習演算法在排斥風險預測的應用
  • 利用調節性T細胞療法誘導固態器官移植受者免疫耐受
  • 尋找新型共刺激抑制劑以預防急性移植排斥反應
  • 非侵入性影像診斷技術的進步，用於全面監測移植後器官健康狀況
  • 為移植患者引入基於藥物基因組學分析的個人化免疫抑制療法
  • 透過將人工智慧工具整合到移植免疫學研究中來最佳化長期移植存活率

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章固態器官移植排斥反應市場（依排斥反應類型分類）

  • 急性排斥反應
  • 慢性排斥
  • 超急性排斥

第9章固態器官移植排斥反應市場（依產品/服務分類）

  • 診斷和測試解決方案
    • 血液檢查
    • 影像檢查
    • 組織切片檢查
  • 藥物
    • 抗體
    • 抗代謝物
    • Calcineurin抑制劑
    • 類固醇

第10章 依移植器官類型分類的固態器官移植排斥反應市場

  • 心
  • 腎
  • 肝
  • 肺
  • 胰臟

第11章固態器官移植排斥反應市場（依最終用戶分類）

  • 醫院及移植中心
  • 研究所
  • 專科診所

第12章固態器官移植排斥反應市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章固態器官移植排斥反應市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國固態器官移植排斥反應市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Accord Healthcare Limited
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Biocon
    • Cipla Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Eurofins Transplant Diagnostics
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Globela Pharma
    • Lupin Limited
    • Manus Aktteva Biopharma LLP
    • Natco Pharma Ltd.
    • Novartis AG
    • Panacea Biotec Pharma Ltd.
    • Pfizer Inc.
    • Plexision
    • Sanofi SA
    • Strides Pharma Global Pte Ltd.
    • Thermo Fisher Scientific Inc.
    • Veloxis Pharmaceuticals A/S
    • Zydus Lifesciences Limited
Product Code: MRR-CB04E05661AD

The Solid Organ Transplantation Rejection Market is projected to grow by USD 13.41 billion at a CAGR of 5.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.74 billion
Estimated Year [2025] USD 9.19 billion
Forecast Year [2032] USD 13.41 billion
CAGR (%) 5.50%

Introducing the evolving clinical, diagnostic, and therapeutic environment of solid organ transplant rejection and the strategic imperatives for integrated care pathways and innovation

Solid organ transplantation remains one of the most transformative interventions in modern medicine, yet rejection continues to be a central clinical and operational challenge. As surgical outcomes have improved, attention has shifted to the heterogenous immune responses that lead to acute, chronic, and hyperacute rejection, each of which demands distinct diagnostic, monitoring, and therapeutic approaches. The evolving interplay between immunology, diagnostics, and therapeutics requires clinicians, hospital systems, manufacturers, and payers to re-evaluate care pathways and the supporting infrastructure.

In recent years, advances in molecular diagnostics and noninvasive monitoring have opened new possibilities for earlier detection and individualized immunosuppression, while therapeutic innovations seek to balance efficacy with long-term safety. At the same time, differences in transplanted organs-such as the physiologic and immunologic nuances of heart, kidney, liver, lung, and pancreas transplantation-shape both clinical practice and product development. Consequently, stakeholders must synthesize evidence across rejection type, diagnostic and medication offerings, organ-specific considerations, and the diverse environments in which transplant care is delivered. This introduction sets the context for a focused examination of those elements and frames the priorities that will guide clinical effectiveness, patient outcomes, and system-level value creation.

Transformative shifts in diagnostics, therapeutics, digital integration, regulatory focus, and cross-sector collaboration that are reframing how transplant rejection is detected and managed

The landscape of transplant rejection management is undergoing several parallel transformations that together are redefining standards of care. One primary shift is the maturation of precision diagnostics: blood-based assays, advanced imaging modalities, and refined tissue biopsy techniques are converging to enable earlier and more specific detection of immune-mediated injury. These diagnostic advances are complemented by improvements in immunomodulatory medications, including refined antibody therapies, targeted antimetabolites, optimized calcineurin inhibitor regimens, and steroid minimization strategies, creating opportunities for more individualized immunosuppression that reduces both rejection and long-term toxicity.

Alongside clinical innovations, digital health and data integration are changing how monitoring and decision-making occur. Remote patient monitoring, algorithmic risk stratification, and interoperable electronic health records are facilitating more proactive care and tighter coordination among transplant centers, specialty clinics, and research institutes. Regulatory and reimbursement environments are also shifting their focus toward evidence of clinical utility and cost-effectiveness, which incentivizes the development of diagnostics and therapeutics that demonstrate clear impact on outcomes. Finally, partnerships across industry, academic centers, and clinical networks are accelerating translational research and multicenter validation of novel tools. Taken together, these transformative shifts are producing a more responsive, evidence-driven approach to preventing and managing acute, chronic, and hyperacute rejection across organ types.

Assessing how United States tariff changes beginning in 2025 are reshaping procurement, manufacturing footprints, international collaborations, and supply chain resilience for transplant care

The introduction of tariffs in the United States beginning in 2025 has compounded preexisting supply chain pressures and prompted a reevaluation of procurement strategies for many stakeholders involved in transplantation care. Devices and reagents used in blood tests, imaging platforms, and tissue biopsy processing often rely on multinational supply chains; increased import costs and customs complexity have therefore influenced sourcing decisions, inventory practices, and supplier diversification. As a result, some transplant centers and specialty clinics have accelerated efforts to localize critical inventories, negotiate multi-year supplier agreements, or adopt alternative technologies with more domestically available components.

In addition to procurement adaptations, tariffs have affected collaborative dynamics with international research partners and manufacturers. Cross-border clinical trials and technology transfer arrangements have required greater attention to total landed cost, regulatory alignment, and contingency planning. Manufacturers and distributors have responded by reassessing manufacturing footprints, increasing redundancy in critical nodes of the supply chain, and prioritizing transparency in lead times and component provenance. While these adjustments have the potential to increase resilience, they also introduce transitional operational costs and require closer coordination between hospitals, transplant centers, and research institutes to maintain uninterrupted access to diagnostics and therapies. Ultimately, the cumulative impact of tariffs has underscored the need for strategic procurement, robust supplier relationships, and operational flexibility across the transplantation ecosystem.

Segment-driven insights synthesizing rejection phenotypes, diagnostic modalities, therapeutic classes, organ-specific considerations, and care setting influences to guide strategic prioritization

A nuanced understanding of market dynamics emerges by examining the key segments that define transplant rejection management. When viewing the field through the lens of rejection type, acute rejection demands rapid diagnostic clarity and responsive immunosuppression, chronic rejection requires long-term monitoring and strategies to mitigate progressive graft deterioration, and hyperacute rejection necessitates immediate perioperative recognition and intervention. Each rejection phenotype thus imposes distinct clinical priorities and technology requirements.

From the perspective of offerings, diagnostics and testing solutions encompass blood tests that permit noninvasive surveillance, imaging tests that characterize structural and perfusion changes, and tissue biopsy procedures that provide histopathologic confirmation; medications include antibody agents that modulate humoral responses, antimetabolites that interfere with lymphocyte proliferation, calcineurin inhibitors that suppress T-cell activity, and steroids used for both induction and rescue therapy. These categories interact differently across organ types: heart, kidney, liver, lung, and pancreas transplantation each present unique immunologic profiles and clinical surveillance needs that influence the choice and sequencing of diagnostics and therapeutics. Finally, end-user settings such as hospitals and transplant centers deliver comprehensive perioperative and long-term care, research institutes drive translational innovation and validation studies, and specialty clinics often support outpatient monitoring and medication optimization. An integrated view of these segmentations clarifies where clinical unmet needs intersect with technological capabilities and operational realities, enabling stakeholders to prioritize investment, development, and implementation strategies that align with organ-specific and care-setting requirements.

Regional patterns and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine research focus, clinical integration, and access to transplant innovations

Regional variation profoundly affects how innovations in transplant rejection prevention and management are adopted and integrated into care. In the Americas, high-volume transplant centers and established reimbursement pathways often support rapid uptake of advanced diagnostics and novel therapeutics, while regional disparities in access require targeted initiatives to expand capacity and equitable care. Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and health system models; as a result, adoption tends to be uneven, with academic centers and national reference hospitals leading in clinical research and the diffusion of best practices, while other areas focus on pragmatic, resource-efficient approaches.

Across Asia-Pacific, rising transplant volumes and substantial investments in biotechnology and diagnostics have spurred local innovation and manufacturing, contributing to an expanding pipeline of regionally developed tools. However, differences in population demographics, disease etiologies, and care infrastructure mean that clinical pathways and monitoring strategies are often adapted to local contexts. These geographic distinctions also influence collaborative research priorities, the design of multicenter studies, and the scalability of solutions, underscoring the importance of tailoring implementation plans and commercialization strategies to regional strengths, regulatory expectations, and health system realities.

Competitive and collaborative company insights revealing how diagnostics innovators, therapeutic developers, and supply chain strategists are positioning to capture clinical and operational leadership

The competitive landscape in transplant rejection management is characterized by a mix of established healthcare companies and specialized innovators that together drive technological progress and clinical adoption. Diagnostic firms are investing in high-sensitivity blood-based assays and scalable platforms for tissue analysis, while imaging vendors focus on modalities that enhance graft surveillance and functional assessment. Pharmaceutical and biotech companies continue to refine immunosuppressive regimens and advance antibody and small-molecule programs that target specific immune pathways, often collaborating with academic centers to validate clinical endpoints and safety profiles.

Strategic partnerships, co-development agreements, and licensing arrangements are common as organizations seek to combine diagnostic precision with therapeutic innovation. In addition, manufacturers are responding to supply chain pressures by diversifying supplier networks and exploring near-shore manufacturing to reduce vulnerability to international disruptions. Overall, the market exhibits a pragmatic balance between competition and collaboration: firms that demonstrate interoperability with clinical workflows, robust evidence of clinical utility, and reliable supply chains are best positioned to form durable relationships with hospitals, transplant centers, and research institutes.

Actionable recommendations for senior executives and clinical leaders to accelerate diagnostic adoption, strengthen supply chains, align partnerships, and expand equitable access across care settings

Industry leaders should pursue a set of coordinated actions to translate scientific advances into measurable improvements in graft longevity and patient outcomes. First, prioritizing investments in diagnostics that enable earlier, noninvasive detection will improve clinical responsiveness and reduce reliance on more invasive procedures. Secondly, embedding diagnostic-to-therapy algorithms into clinical workflows-supported by interoperable health IT, decision support, and clinician training-will accelerate adoption and improve consistency of care across hospitals, transplant centers, and specialty clinics. Moreover, organizations should pursue strategic partnerships that unite diagnostic makers, pharmaceutical developers, and research institutes to co-design validation studies and real-world evidence programs that demonstrate clinical utility across heart, kidney, liver, lung, and pancreas transplantation.

From an operational perspective, supply chain diversification and transparent supplier relationships are essential to mitigate the downstream effects of trade policies and component shortages. Leaders must also focus on equitable access strategies that address geographic disparities and support capacity building where adoption lags. Finally, corporate and clinical stakeholders should invest in post-market surveillance and longitudinal registries to better understand patterns of acute, chronic, and hyperacute rejection and to refine therapeutic strategies over time. Taken together, these actions will help organizations reduce clinical variability, optimize resource utilization, and expand patient access to state-of-the-art monitoring and treatment.

Transparent mixed-methods research approach integrating peer-reviewed evidence, primary expert interviews, and operational validation to ensure robust and actionable conclusions

The analysis underpinning this report combines a rigorous, mixed-methods research approach designed to ensure credibility, relevance, and practical utility. Secondary research included a systematic review of peer-reviewed clinical literature, regulatory filings, and publicly available technical documentation to characterize diagnostic technologies, therapeutic mechanisms, and clinical management strategies for different rejection phenotypes. This evidence base was supplemented by primary research consisting of structured interviews with transplant clinicians, laboratory directors, procurement officers, and industry executives to capture frontline perspectives on unmet needs, implementation barriers, and practical adoption drivers.

Qualitative findings were validated through expert workshops and cross-checked against operational indicators reported by transplant centers and specialty clinics. Where appropriate, sensitivity analyses and scenario planning were used to explore the effects of supply chain disruptions and policy changes on procurement and clinical continuity. Throughout, quality controls included source triangulation, transparency in assumptions, and iterative review by clinical subject-matter experts to ensure that conclusions reflect current practice and emerging trends in diagnostics, therapeutics, and care delivery.

Conclusion synthesizing clinical and strategic imperatives for improving graft longevity through diagnostics, therapeutics, collaboration, and resilient implementation strategies

Solid organ transplantation sits at a crossroads where scientific innovation, clinical practice, and system-level considerations converge to shape patient outcomes. Advances in diagnostics and therapeutics offer real potential to reduce the incidence and impact of acute, chronic, and hyperacute rejection, yet realizing that potential requires coordinated action across manufacturers, clinicians, health systems, and policymakers. Strategic investments in noninvasive monitoring, evidence generation, interoperable workflows, and resilient supply chains are central to translating scientific progress into routine clinical benefit.

In conclusion, stakeholders that align product development with clinical workflows, prioritize real-world validation, and invest in regional implementation strategies will be best positioned to improve graft survival and patient quality of life. Continued collaboration between hospitals and transplant centers, research institutes, and specialty clinics will drive the next wave of innovation and ensure that technological advances deliver measurable clinical value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of donor-specific biomarkers for early detection of allograft rejection
  • 5.2. Implementation of machine learning algorithms to predict rejection risk based on patient clinical data
  • 5.3. Use of regulatory T cell therapies to induce immune tolerance in solid organ transplant recipients
  • 5.4. Exploration of novel costimulation blockade agents to prevent acute graft rejection episodes
  • 5.5. Advances in noninvasive imaging techniques for comprehensive post-transplant organ health monitoring
  • 5.6. Adoption of personalized immunosuppression regimens guided by pharmacogenomic profiling for transplant patients
  • 5.7. Integration of artificial intelligence tools into transplant immunology research to optimize long-term graft survival

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solid Organ Transplantation Rejection Market, by Rejection Type

  • 8.1. Acute Rejection
  • 8.2. Chronic Rejection
  • 8.3. Hyperacute Rejection

9. Solid Organ Transplantation Rejection Market, by Offering

  • 9.1. Diagnosis & Testing Solutions
    • 9.1.1. Blood Tests
    • 9.1.2. Imaging Tests
    • 9.1.3. Tissue Biopsy
  • 9.2. Medications
    • 9.2.1. Antibodies
    • 9.2.2. Antimetabolites
    • 9.2.3. Calcineurin Inhibitors
    • 9.2.4. Steroids

10. Solid Organ Transplantation Rejection Market, by Type Of Organ Transplant

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Solid Organ Transplantation Rejection Market, by End User

  • 11.1. Hospitals & Transplant Centers
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Solid Organ Transplantation Rejection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Solid Organ Transplantation Rejection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Solid Organ Transplantation Rejection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Accord Healthcare Limited
    • 15.3.3. Asahi Kasei Corporation
    • 15.3.4. Astellas Pharma Inc.
    • 15.3.5. Biocon
    • 15.3.6. Cipla Ltd.
    • 15.3.7. Dr. Reddy's Laboratories Ltd.
    • 15.3.8. Eurofins Transplant Diagnostics
    • 15.3.9. F. Hoffmann-La Roche Ltd.
    • 15.3.10. GlaxoSmithKline PLC
    • 15.3.11. Globela Pharma
    • 15.3.12. Lupin Limited
    • 15.3.13. Manus Aktteva Biopharma LLP
    • 15.3.14. Natco Pharma Ltd.
    • 15.3.15. Novartis AG
    • 15.3.16. Panacea Biotec Pharma Ltd.
    • 15.3.17. Pfizer Inc.
    • 15.3.18. Plexision
    • 15.3.19. Sanofi S.A.
    • 15.3.20. Strides Pharma Global Pte Ltd.
    • 15.3.21. Thermo Fisher Scientific Inc.
    • 15.3.22. Veloxis Pharmaceuticals A/S
    • 15.3.23. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. SOLID ORGAN TRANSPLANTATION REJECTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 272. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 273. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 274. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 275. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 276. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 277. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPL